The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers

The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers

Chronic myeloid leukemia is one of the onco-hematologic diseases in which the identification of disease markers and therapeutic advances have been particularly impactful. Despite this, significant gaps remain in our understanding of disease pathogenesis, progression, mechanisms of immune escape, and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anna Sicuranza, Alessia Cavalleri, Simona Bernardi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Oncology
Subjects:	CML biological markers BCR::ABL1 ASXL1 EVs CD26
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1546813/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response
by: Rebecca Warfvinge, et al.
Published: (2024-11-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents
by: Sarah K. Tasian, et al.
Published: (2025-12-01)

Chronic myeloid leukemia in childhood: a case report
by: Uma Bhatta, et al.
Published: (2021-09-01)

The Unusual Presentation of Bilateral Proptosis Presents a Dilemma in the Case of Juvenile Myelomonocytic Leukemia
by: Himanshu Gohatre, et al.

BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake
by: Caterina Mancini, et al.
Published: (2025-05-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

Using the Minor Variant Finder software to identify and quantify the allelic burden level of somatic mutations in oncohematologic diseases
by: T. N. Subbotina, et al.
Published: (2020-07-01)

Evaluating the correlation of Age and Gender with the Hematological Parameters of the Chronic Myeloid Leukemia Patients
by: Farooq I. Mohammad, et al.
Published: (2025-04-01)

Evolution of therapeutic approaches in patients with chronic myeloid leukemia and T315I mutation
by: A. G. Turkina, et al.
Published: (2024-12-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Characteristics of BCR::ABL1 kinase domain mutations in Vietnamese chronic myeloid leukemia patients
by: Phu Chi Dung, et al.
Published: (2025-01-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells
by: Masanobu Tsubaki, et al.
Published: (2025-01-01)

A decade-long analysis of 98 chronic myeloid leukemia patients: Laboratory data and clinical progress at a single center
by: Nabihah Mohd Shakri, et al.
Published: (2025-01-01)

A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia
by: Valeria Bica, et al.
Published: (2025-04-01)

MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURE
by: Sameen Shahid, et al.
Published: (2024-03-01)

Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase
by: Sekulić Borivoj, et al.
Published: (2022-01-01)

Efficacy of Bosutinib therapy as a second line in the treatment of chronic myeloid leukemia: A single-center study
by: Alaa Fadhil Alwan, et al.
Published: (2025-01-01)

BCR‐ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph+ ALL
by: Wen‐bin Cao, et al.
Published: (2018-06-01)

Genetic profile of ASXL1 gene in risk assessment in acute myeloid leukemia
by: Salem Ahmed Bamusa, et al.
Published: (2025-07-01)

The comparative analysis of BCR-ABL/ABL detection by real-time quantitative PCR and automated GeneXpert Dx System in chronic myeloid leukemia patients with major and complete molecular response
by: S. A. Smirnikhina, et al.
Published: (2014-07-01)

Glivec: A New Treatment Modality for CML: A Case History
by: Jürg Zimmermann
Published: (2002-08-01)

Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches
by: Dilinazi Abulaiti, et al.
Published: (2024-12-01)

In silico development of HASDI-G2 as a novel agent for selective recognition of the DNA sequence
by: Andrii Zaremba, et al.
Published: (2025-03-01)

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia
by: Begoña San José Ruiz, et al.
Published: (2015-01-01)

Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia
by: Denčić-Fekete Marija, et al.
Published: (2021-01-01)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
by: Ćojbašić Irena, et al.
Published: (2011-01-01)

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia
by: Yiming Cai, et al.
Published: (2025-07-01)

Predicting drug resistance
by: Nicole S Arellano, et al.
Published: (2024-11-01)

CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES
by: G. Sh. Safuanova, et al.
Published: (2019-05-01)

Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)
by: VV Tikhonova, et al.
Published: (2018-07-01)

PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells
by: ES Kolotova, et al.
Published: (2016-01-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: K. Kotlyarchuk, et al.
Published: (2015-09-01)

Discovery of <i>N</i>-(2-Acetamidobenzo[<i>d</i>]thiazol-6-yl)-2-phenoxyacetamide Derivatives as Novel Potential BCR-ABL1 Inhibitors Through Structure-Based Virtual Screening
by: Shuaixing Wang, et al.
Published: (2025-02-01)

A FUSION OF NUP214 TO ABL1 ON AMPLIFIED EPISOMES IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: CASE REPORT AND LITERATURE REVIEW
by: Jiantuo Liu, et al.
Published: (2025-07-01)

Novel e4a2 BCR∷ABL1 transcript with insertion of CSE1L exons 9 and 10 in a CML patient: a case report
by: Sara Di Giusto, et al.
Published: (2025-08-01)

A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
by: Zhen-Yu Xiong, et al.
Published: (2024-12-01)

An interesting case of chronic myeloid leukemia with twists and turns
by: Thulasi Raman Ramalingam, et al.
Published: (2024-12-01)

Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate
by: Pratik Deb, et al.
Published: (2014-01-01)